SENS - Senseonics Holdings, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
2.5125
-0.0975 (-3.74%)
As of 3:16PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.6100
Open2.6100
Bid0.0000 x 800
Ask0.0000 x 2200
Day's Range2.5100 - 2.6600
52 Week Range2.1500 - 5.2900
Volume1,629,665
Avg. Volume1,777,644
Market Cap444.607M
Beta (3Y Monthly)1.31
PE Ratio (TTM)N/A
EPS (TTM)-0.5970
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.80
Trade prices are not sourced from all markets
  • Senseonics Unveils Eversense Bridge Program in the U.S.
    Zacksyesterday

    Senseonics Unveils Eversense Bridge Program in the U.S.

    The Eversense Bridge program aligns with Senseonics' (SENS) strategy of offering innovative yet affordable and hassle-free medical care to diabetic patients.

  • Business Wire4 days ago

    Senseonics Launches the Eversense® Bridge Patient Access Program in the U.S.

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, has announced the launch of the Eversense Bridge Program. Under the program, patients can access the Eversense CGM System, the only long-term CGM that lasts up to 90 days, for only $99* plus the cost of the sensor placement by the healthcare provider. “The Eversense Bridge Program is an important strategic initiative with the goal of providing access to eligible patients who have high out-of-pocket costs, are waiting for a favorable coverage policy, or have been denied insurance coverage for Eversense,” said Tim Goodnow, President and CEO of Senseonics.

  • Is the Options Market Predicting a Spike in Senseonics Holdings (SENS) Stock?
    Zacks7 days ago

    Is the Options Market Predicting a Spike in Senseonics Holdings (SENS) Stock?

    Investors need to pay close attention to Senseonics Holdings (SENS) stock based on the movements in the options market lately.

  • Thomson Reuters StreetEvents11 days ago

    Edited Transcript of SENS earnings conference call or presentation 12-Mar-19 8:30pm GMT

    Q4 2018 Senseonics Holdings Inc Earnings Call

  • What Kind Of Share Price Volatility Should You Expect For Sensor Technologies Corp. (CNSX:SENS)?
    Simply Wall St.11 days ago

    What Kind Of Share Price Volatility Should You Expect For Sensor Technologies Corp. (CNSX:SENS)?

    If you own shares in Sensor Technologies Corp. (CNSX:SENS) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...

  • Senseonics Holdings, Inc. (SENS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool14 days ago

    Senseonics Holdings, Inc. (SENS) Q4 2018 Earnings Conference Call Transcript

    SENS earnings call for the period ending December 31, 2018.

  • Senseonics Holdings (SENS) Reports Q4 Loss, Lags Revenue Estimates
    Zacks14 days ago

    Senseonics Holdings (SENS) Reports Q4 Loss, Lags Revenue Estimates

    Senseonics (SENS) delivered earnings and revenue surprises of 73.33% and -8.75%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press14 days ago

    Senseonics: 4Q Earnings Snapshot

    The Germantown, Maryland-based company said it had a loss of 4 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Business Wire14 days ago

    Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results

    Senseonics Holdings, Inc. , a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, today reported financial results for the fourth quarter and full year ended December 31, 2018.

  • Did Changing Sentiment Drive Senseonics Holdings’s (NYSEMKT:SENS) Share Price Down By 16%?
    Simply Wall St.15 days ago

    Did Changing Sentiment Drive Senseonics Holdings’s (NYSEMKT:SENS) Share Price Down By 16%?

    Senseonics Holdings, Inc. (NYSEMKT:SENS) shareholders should be happy to see the share price up 27% in the last month. But that doesn't change the fact that the returns over theRead More...

  • Business Wire20 days ago

    Senseonics Announces Appointment of Francine R. Kaufman, M.D. as Chief Medical Officer

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the appointment of Francine R. Kaufman, M.D. as Chief Medical Officer, effective immediately. “We are pleased to have Fran join the executive leadership team at Senseonics. As Chief Medical Officer, she will be instrumental in helping drive forward our innovation platform and the clinical value proposition of the Eversense system,” said Tim Goodnow, President and CEO of Senseonics.

  • Business Wire21 days ago

    Senseonics Eversense® CGM Launches Integration with Glooko

    Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the integration of Eversense CGM data into the Glooko diabetes data management platform.

  • Business Wire26 days ago

    Senseonics to Participate in the Cowen Health Care Conference

    Senseonics Holdings, Inc. , a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, today announced the company plans to participate in the upcoming Cowen Health Care Conference in Boston, MA.

  • Business Wirelast month

    Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2018 Earnings Release and Conference Call for March 12, 2019 at 4:30 p.m. Eastern Time

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it plans to release its fourth quarter and full year 2018 financial results after market close on Tuesday, March 12, 2019. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease.

  • Business Wirelast month

    Senseonics Announces Partnership with Geo-Med to Provide Veterans Access to Eversense CGM

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today has announced that it has partnered with Geo-Med, LLC, a verified Service-Disabled Veteran-Owned Small Business (SDVOSB) to provide access to Eversense CGM to more than 9 million covered veterans and U.S. government personnel. “We are pleased to partner with Geo-Med in providing veterans with diabetes access to the latest CGM technology available.

  • Business Wire2 months ago

    Senseonics Announces Extension of Distribution Agreement with Roche Diabetes Care

    Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced an extension of its distribution agreement with Roche Diabetes Care. Under terms of the extended agreement, Roche will continue its role as Senseonics exclusive distributor in Europe, the Middle East and Africa, excluding Scandinavia and Israel.

  • Business Wire2 months ago

    Senseonics Eversense CGM Sensor Receives Indication for MRI

    Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today has announced that they received notice from FDA that the Eversense Sensor is no longer contraindicated for MRI scanning*. “Now patients using Eversense CGM do not need to worry about an emergency MRI or delay getting a scheduled MRI based on their glucose sensor.

  • GlobeNewswire2 months ago

    Detailed Research: Economic Perspectives on Inovalon, Merit Medical, Senseonics, Ocular Therapeutix, The Hartford Financial Services Group, and Synopsys — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Jan. 22, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire3 months ago

    Senseonics Appoints Jon D. Isaacson as Chief Financial Officer

    Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the appointment of Jon D. Isaacson as the company’s Chief Financial Officer, effective immediately. Concurrently, and as previously announced, R. Don Elsey has stepped down from the position and will continue in an advisory role to ensure an orderly transition and completion of the company’s annual SEC filings for the 2018 fiscal year. Mr. Isaacson has nearly 25 years of experience in financial leadership roles.

  • ACCESSWIRE3 months ago

    Senseonics Holdings Commercial Development of Eversense, Analysts Review and Target

    NEW YORK, NY / ACCESSWIRE / January 7, 2019 / Traders News Source, aleading independent equity research and corporate access firm focused on smalland mid-cap public companies is issuing a comprehensive report on Senseonics Holdings, Inc.(NYSE: SENS) is a medical technology company focused on the design, development, and commercialization of glucose monitoring products designed to help people with diabetes. The Eversense® CGM System received PMA approval from the FDA for up to 90 days of continuous use and is available in the United States. The Eversense® CGM XL System received CE mark for up to 180 days of continuous use and is available in Europe.

  • Business Wire3 months ago

    Senseonics Announces First Study Participant Implanted in the U.S. as Part of the PROMISE 180-Day Sensor Clinical Study and the Submission of Key PMA Supplements to the FDA to Advance Current 90-Day Product

    Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that the extended life Eversense® XL sensor that lasts up to 180 days has been implanted in the first U.S. study participant as part of the clinical trial for pre-market application submission to the Food and Drug Administration. The PROMISE Clinical Study is intended to evaluate the safety and efficacy of the Eversense CGM system in people with diabetes over a 180-day period. Approximately 180 study participants at up to 15 locations across the United States are planned to enroll in the study.

  • Do Hedge Funds Love Senseonics Holdings, Inc. (SENS)?
    Insider Monkey3 months ago

    Do Hedge Funds Love Senseonics Holdings, Inc. (SENS)?

    Is Senseonics Holdings, Inc. (NYSE:SENS) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk […]

  • Implied Volatility Surging for Senseonics Holdings (SENS) Stock Options
    Zacks3 months ago

    Implied Volatility Surging for Senseonics Holdings (SENS) Stock Options

    Senseonics Holdings (SENS) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Business Wire4 months ago

    Senseonics Holdings, Inc. Announces Retirement of Chief Financial Officer

    Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the retirement of Chief Financial Officer, R. Don Elsey. “Don has been an important part of the growth of Senseonics as our CFO, and we thank him for his service and high level of professionalism throughout his tenure at Senseonics,” said Tim Goodnow, President and Chief Executive Officer. “It has been a pleasure working with the dedicated and talented team at Senseonics,” stated Don Elsey, Chief Financial Officer.

  • Business Wire4 months ago

    Eversense CGM Wins a 2018 “Best of What’s New” Award

    Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today has announced that the Eversense® Continuous Glucose Monitoring (CGM) System has been awarded one of Popular Science’s 2018 “Best of What’s New” Awards in the Health category. Each year, Popular Science magazine reviews thousands of new products and innovations in order to choose the top 100 winners across 10 categories.